SEC 13F Intelligence

Managers / Q3 2023 · view latest →

RTW INVESTMENTS, LP

CIK 0001493215 · 40 10TH AVENUE, 7TH FLOOR, NEW YORK, NY, 10014 · 646-597-6980

Reported Value
$4.7B
Q3 2023
Positions
67
Filings on Record
33
2019–present window
Filed
Nov 14, 2023
original filing

Summary

Rtw Investments, LP reported $4.7B in U.S.-listed holdings across 67 positions for Q3 2023.

Its largest position, RCKT, represents 7.6% of the portfolio.

Compared with Q2 2023, the fund opened 10 new positions and exited 5.

Portfolio Metrics

Turnover
+11.7%
vs prior filed quarter
Top-10 Concentration
+55.8%
share of reported value
Largest Position
+7.6%
Rocket Pharmaceuticals
New / Exited
10 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $1.1BQ4 ’18Q1 ’19: $1.5BQ2 ’19: $1.9BQ3 ’19: $1.7BQ4 ’19: $2.7BQ4 ’19Q1 ’20: $2.3BQ2 ’20: $3.6BQ3 ’20: $4.2BQ4 ’20: $6.0BQ4 ’20Q1 ’21: $6.4BQ2 ’21: $6.6BQ3 ’21: $6.6BQ4 ’21: $6.8BQ4 ’21Q1 ’22: $4.8BQ2 ’22: $3.9BQ3 ’22: $4.3BQ4 ’22: $4.9BQ4 ’22Q1 ’23: $4.8BQ2 ’23: $5.3BQ3 ’23: $4.7BQ4 ’23: $6.4BQ4 ’23Q1 ’24: $6.8BQ2 ’24: $6.5BQ3 ’24: $6.9BQ4 ’24: $6.6BQ4 ’24Q1 ’25: $6.5BQ2 ’25: $7.0BQ3 ’25: $8.1BQ4 ’25: $10.0BQ4 ’25Q1 ’26: $10.0Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 80.2%ADR: 11.9%Other: 7.9%Equity WRT: 0.0%
  • Common Stock · 80.2% · $3.8B
  • ADR · 11.9% · $566M
  • Other · 7.9% · $373M
  • Equity WRT · 0.0% · $59,500

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SG7SAGE THERAPEUTICS INCNEW+5.15M5.15M+$106M$106M
TSHATAYSHA GENE THERAPIES INCNEW+16.89M16.89M+$53M$53M
APGEAPOGEE THERAPEUTICS INCNEW+2.14M2.14M+$46M$46M
ALKERMES PLCNEW+889.1K889.1K+$25M$25M
SWAVUSDSHOCKWAVE MED INCNEW+124.0K124.0K+$25M$25M
ALLURION TECHNOLOGIES INCNEW+3.46M3.46M+$15M$15M
SYKSTRYKER CORPORATIONNEW+28.0K28.0K+$8M$8M
SGMTSAGIMET BIOSCIENCES INCNEW+400.3K400.3K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RCKTROCKET PHARMACEUTICALS INChistory →COM7.65%$362M17.69M
2IMCRIMMUNOCORE HLDGS PLChistory →ADS6.68%$316M6.10M
3AXSMAXSOME THERAPEUTICS INChistory →COM6.62%$314M4.49M
4ALNYALNYLAM PHARMACEUTICALS INChistory →COM6.29%$298M1.68M
5MRTXEURMIRATI THERAPEUTICS INChistory →COM6.22%$295M6.77M
6ARGXARGENX SEhistory →SPONSORED ADR5.26%$249M507.2K
7ACADACADIA PHARMACEUTICALS INChistory →COM5.09%$241M11.58M
8BRKRBRUKER CORPhistory →COM4.45%$211M3.38M
9RAREULTRAGENYX PHARMACEUTICAL INhistory →COM4.07%$193M5.41M
10PENPENUMBRA INChistory →COM3.44%$163M673.4K
11PTCTPTC THERAPEUTICS INChistory →COM3.42%$162M7.24M
12TMOTHERMO FISHER SCIENTIFIC INChistory →COM3.10%$147M290.3K
13MASI*MASIMO CORPhistory →COM2.78%$132M1.50M
14ESTABLISHMENT LABS HLDGS INCCOM2.58%$122M2.49M
15NTRANATERA INChistory →COM2.48%$117M2.65M
16VCELVERICEL CORPhistory →COM2.33%$110M3.29M
17SG7SAGE THERAPEUTICS INChistory →COM2.24%$106M5.15M
18TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW2.01%$95M3.46M
19PTGXPROTAGONIST THERAPEUTICS INChistory →COM1.91%$90M5.42M
20CYTKCYTOKINETICS INChistory →COM NEW1.60%$76M2.57M
21AVADEL PHARMACEUTICALS PLCSPONSORED ADR1.55%$74M7.14M
22TXG10X GENOMICS INChistory →CL A COM1.32%$63M1.52M
23TSHATAYSHA GENE THERAPIES INChistory →COM SHS1.13%$53M16.89M
24TARSTARSUS PHARMACEUTICALS INChistory →COM1.08%$51M2.88M
25OBIOORCHESTRA BIOMED HLDGS INChistory →COM1.03%$49M5.62M
26IM8NINSMED INChistory →COM PAR $.010.99%$47M1.87M
27MERUS N VCOM0.99%$47M2.00M
28APGEAPOGEE THERAPEUTICS INChistory →COM0.96%$46M2.14M
29MDGLMADRIGAL PHARMACEUTICALS INChistory →COM0.95%$45M309.5K
30RNAGBPAVIDITY BIOSCIENCES INChistory →COM0.90%$43M6.69M
31GH RESEARCH PLCORDINARY SHARES0.71%$33M3.33M
32MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD0.60%$29M500.0K
33FULCFULCRUM THERAPEUTICS INChistory →COM0.55%$26M5.82M
34ILMNILLUMINA INChistory →COM0.54%$26M188.1K
35ALKERMES PLCSHS0.53%$25M889.1K
36AXNX*AXONICS INChistory →COM0.52%$25M442.5K
37SWAVUSDSHOCKWAVE MED INChistory →COM0.52%$25M124.0K
38SCPHSCPHARMACEUTICALS INChistory →COM0.50%$23M3.30M
39ROIVANT SCIENCES LTDSHS0.38%$18M1.55M
40STOKSTOKE THERAPEUTICS INChistory →COM0.36%$17M4.39M
41ALLURION TECHNOLOGIES INCCOM SHS0.31%$15M3.46M
42GHGUARDANT HEALTH INChistory →COM0.31%$15M500.9K
43PMVPPMV PHARMACEUTICALS INChistory →COM0.31%$15M2.38M
44UROGEN PHARMA LTDCOM0.25%$12M857.5K
45CUTREURCUTERA INChistory →COM0.23%$11M1.85M
46MISTMILESTONE PHARMACEUTICALS INhistory →COM0.21%$10M3.26M
47ACELYRIN INCCOM0.21%$10M978.3K
48IMMATICS N.VSHS0.21%$10M845.0K
49OMGBPOUTSET MED INCCOM0.19%$9M808.7K
50MLYSMINERALYS THERAPEUTICS INCCOM0.19%$9M922.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$10.0B88May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$10.0B91Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$8.1B74Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$7.0B73Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$6.5B68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$6.6B72Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$6.9B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$6.5B68Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$6.8B69May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$6.4B64Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$4.7B67Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$5.3B62Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$4.8B60May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$4.9B77Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$4.3B86Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$3.9B107Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$4.8B106May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$6.8B124Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$6.6B120Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$6.6B113Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$6.4B111May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$6.0B102Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$4.2B90Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$3.6B77Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$2.3B65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019REVEALED$2.7B61Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.7B60Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.9B52Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.5B50May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018REVEALED$1.1B48Feb 15, 2019RESTATEMENTchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.